Psoriatic Arthritis – Unmet Need – Detailed, Expanded Analysis (US/EU)
TNF-alpha inhibitors remain the primary choice for psoriatic arthritis (PsA) after conventional DMARD failure, but competing biologics such as IL-17 inhibitors (Cosentyx, Taltz), IL-12/23 inhibitors (Stelara), IL-23 inhibitors (Tremfya, Skyrizi), and targeted oral therapies (Otezla, Xeljanz, Rinvoq) are increasingly challenging the dominance of TNF-alpha inhibitors in treating PsA. Recognizing gaps in PsA treatment and focusing on product differentiation may play a crucial role in an agent’s success in this competitive PsA space. This report outlines key unmet needs and offers tools for strategic decision-making in the PsA therapy market.
QUESTIONS ANSWERED
- How do current therapies perform on key treatment drivers and goals for PsA?
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities in PsA?
- What are the prevailing areas of unmet need and opportunity in the PsA market?
- What trade-offs across key drug attributes and price are acceptable to rheumatologists and dermatologists for a hypothetical new PsA drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European rheumatologists and dermatologists fielded in February 2024
Key companies: AbbVie, Amgen, Pfizer, Johnson & Johnson Innovative Medicine, Novartis, Eli Lilly
Key drugs: Humira, Cosentyx, Taltz, Stelara, Tremfya, Otezla, Rinvoq
Rohit Rout, M.Pharm., Research Associate, Immune and Inflammation. Mr. Rout joined as an intern on the China-In-Depth team at Clarivate, where he performed secondary market research for China’s biopharmaceutical market. Before joining Clarivate, he was an associate scientist in the biopharmaceutics (IVIVC) department at Lupin Pvt. Ltd. He holds an M.Pharm. degree in pharmaceutics from the Birla Institute of Technology and Science in Pilani, India.